argenx

argenx is a global immunology biopharmaceutical company focused on developing antibody-based therapies for severe autoimmune diseases. Founded in 2008, the firm utilizes proprietary antibody discovery technology to create human therapeutic antibodies. Its primary focus is on addressing unmet medical needs through clinical-stage biopharmaceutical innovation. Meet argenx's team to understand the leadership driving these scientific advancements.

The company maintains a robust operational footprint with 3 global locations, supporting a workforce of 1,000-5,000 employees. Learn about argenx's global headquarters for detailed geographic and operational insights. The organization is currently scaling its infrastructure to support the global distribution of its lead product, VYVGART (efgartigimod), an FcRn blocker currently approved in over 30 countries for treating generalized myasthenia gravis, CIDP, and ITP.

argenx is aggressively pursuing its "Vision 2030" strategy, which targets 50,000 patients treated across 10 labeled indications. The pipeline includes advanced candidates such as empasiprubart, a complement inhibitor, and adimanebart, a MuSK agonist. The company reported $4.2B in revenue for 2025, reflecting strong market adoption of its therapeutic portfolio. Explore financial highlights to review detailed performance metrics and funding history, including significant stock offerings that have fueled its R&D expansion and clinical development programs. This strategic growth trajectory underscores the company's commitment to long-term value creation in the immunology sector.